Viewing Study NCT04704934

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:22 AM
Ignite Modification Date: 2026-01-08 @ 2:12 AM
Study NCT ID: NCT04704934
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-10
First Post: 2021-01-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Sponsor: Daiichi Sankyo
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Gastric Cancer, Adenocarcinoma View
None Gastroesophageal Junction Adenocarcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Gastric Cancer, Adenocarcinoma View
None Gastroesophageal Junction Adenocarcinoma View
None Trastuzumab deruxtecan View
None T-DXd View
None DS-8201a View
None Ramucirumab View
None Paclitaxel View